Shots:
- Dizal has reported the topline P-III (WU-KONG28) trial data assessing Zegfrovy monotx. (QD, PO) vs Pt-based CT as the 1L treatment of pts with advanced NSCLC harboring EGFR exon 20 insertion mutations across Asia, EU, North America & South America
- The trial met its 1EP of improved PFS, assessed by BICR, plus showed superiority across all 2EPs, incl. cORR, DOR, & DCR. Detailed data will be submitted for presentation at an upcoming conference
- Additionally, Dizal is planning to engage with regulatory authorities for potential NDA submissions based on P-III (WU-KONG28) trial results
Ref: PRnewswire| Image: Dizal | Press Release
Related News: Dizal Receives the US FDA’s Accelerated Approval for Zegfrovy (Sunvozertinib) to Treat EGFRm NSCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
